Cancer Blood Test Statistics in US 2026 | Galleri Test, Accuracy, Cancer Detection & Key Facts

Cancer Blood Test in US data show that GRAIL’s Galleri multi-cancer early detection test posted a 35.0% sensitivity and 99.85% specificity in its registrational PATHFINDER 2 study, the figures an FDA advisory panel reviewed this month ahead of a premarket approval decision. The panel voted 7-2 that the test’s benefits outweigh its risks, while the full 35,878-participant PATHFINDER 2 cohort showed a 6.5-fold increase in cancers found when Galleri was added to standard screening.

Cancer Blood Test in America 2026

Cancer Blood Test in US tracking center almost entirely on multi-cancer early detection (MCED) technology, a category of blood-based screening tools designed to catch dozens of cancer types with a single draw. GRAIL’s Galleri test remains the most studied product in this space, backed by more than 380,000 participants across its combined clinical evidence program, including the landmark NHS-Galleri randomized controlled trial in the United Kingdom. The test analyzes cell-free DNA in the blood for cancer-specific methylation patterns and can predict the tissue of origin with greater than 90% accuracy when a cancer signal is detected.

This month’s FDA advisory panel review marks the most significant regulatory milestone yet for the technology, evaluating Galleri’s premarket approval application submitted in January 2026. Cancer Blood Test Statistics in US compiled below cover accuracy by study, performance by cancer stage, the FDA review outcome, cost and insurance coverage, and how Galleri compares with competing tests now reaching the market.

Multi-cancer early detection tests matter to the broader cancer-screening landscape because most existing screening tools, mammograms, colonoscopies, Pap smears, and low-dose CT scans, each cover exactly one cancer type. Nearly 70% of annual US cancer cases and deaths occur in cancer types with no equivalent recommended screening test at all, which is the core unmet need every company in this space is racing to address. A single blood draw capable of flagging dozens of cancer types at once would, in theory, close much of that gap, provided the underlying accuracy holds up under regulatory scrutiny and real-world use.

Interesting Facts About Cancer Blood Test in US 2026

Source: FDA advisory panel briefing documents and GRAIL PATHFINDER 2 clinical trial data, September 2026.

The Cancer Blood Test Statistics in US shown here reflect two different analytical lenses researchers use to evaluate the same underlying test. The FDA’s own review of PATHFINDER 2 data reported a 35.0% sensitivity figure across all cancers diagnosed within 12 months, while GRAIL’s own presentation of the full cohort at the 2026 ASCO Annual Meeting emphasized a considerably higher 69.8% episode sensitivity specifically for the 12 cancers responsible for two-thirds of US cancer deaths. Both figures are accurate; they simply measure different subsets of the same trial population using different endpoints.

That distinction matters for anyone trying to interpret Galleri’s real-world reliability. A 77% positive predictive value in the FDA’s PATHFINDER 2 analysis means that when the test does flag a cancer signal, it’s confirmed as true cancer more often than not, but the sensitivity figures make clear the test still misses a meaningful share of cancers present at the time of testing, particularly earlier-stage disease that carries the best treatment odds.

Galleri Test Accuracy Statistics by Study 2026

Sensitivity Reported Across Key Studies
FDA Review, PATHFINDER 2 (all cancers)      |███████████████ 35.0%
NHS-Galleri (FDA review)                    |█████████████ 31.6%
GRAIL ASCO, all cancers                     |█████████████████ 39.3%
GRAIL ASCO, 12 high-mortality cancers       |███████████████████████████████ 69.8%

Source: FDA advisory panel briefing materials and GRAIL 2026 ASCO Annual Meeting presentation.

The gap between the FDA’s 35.0% sensitivity figure and GRAIL’s own 69.8% figure for high-mortality cancers isn’t a contradiction so much as a difference in scope. The FDA’s number covers every cancer type detected across the full trial population, while GRAIL’s higher figure narrows the analysis specifically to the 12 cancer types responsible for the majority of US cancer deaths, a subset where the test performs meaningfully better. Both the PATHFINDER 2 and NHS-Galleri specificity figures land above 99.7%, meaning false positives remain rare regardless of which sensitivity figure gets emphasized.

The 66.2% to 77% range for positive predictive value across the two pivotal studies tells patients and clinicians what actually happens after a positive result: somewhere between two-thirds and just over three-quarters of positive Galleri signals are ultimately confirmed as real cancer following diagnostic workup. That leaves a meaningful share of false positives that still require follow-up imaging, biopsies, or other diagnostic evaluation before a patient can be cleared, a burden researchers have tracked closely given the anxiety and cost such workups can create.

Galleri Test Performance by Cancer Stage 2026

Sensitivity by Stage at Diagnosis (PATHFINDER, Lancet 2023)
Stage I    |███████ 16.8%
Stage II   |████████████████ 40%
Stage III  |█████████████████████████ 65%
Stage IV   |███████████████████████████████████ 90.1%

Source: PATHFINDER study, published in The Lancet, 2023, with 2026 GRAIL follow-up data.

The stage-dependent sensitivity pattern shown here is the single most important nuance in any conversation about Galleri’s clinical value. Detecting only 16.8% of Stage I cancers means the test misses roughly five out of every six of the earliest, most treatable tumors, while catching 90.1% of Stage IV cancers, disease that has already spread and carries far poorer prognosis regardless of when it’s found. That pattern reflects a basic biological reality: tumors shed more detectable cell-free DNA into the bloodstream as they grow larger and more advanced.

GRAIL has pointed to the 71% figure from PATHFINDER 2, the share of newly detected cancers found in Stages I through III combined, as evidence the test still adds meaningful early-detection value despite its Stage I limitations. Critics of that framing note that combining Stages I, II, and III together can obscure just how weak the Stage I detection rate remains on its own, since a cancer caught at Stage III is a very different clinical outcome than one caught at Stage I, even though both count toward the same combined statistic.

The stage-shift argument also depends heavily on assumptions about how quickly a missed Stage I cancer would otherwise be caught through existing screening or symptom-driven diagnosis. A microsimulation model published in the journal Cancer in late 2025 attempted to project the ten-year population-level impact of adding MCED testing to existing screening protocols, work that regulators and payers are likely to weigh alongside the raw sensitivity figures as they decide how much clinical weight to give a test that still misses the majority of the earliest, most curable tumors.

PATHFINDER 2 Full Cohort Results 2026

PATHFINDER 2 Full Cohort (35,878 participants)
Increase in Cancers Found vs. Standard Screening |███████████████████ Up to 6.5x
New Cancers Found in Stages I-III                |████████████████ 71%
Specificity                                      |████████████████████ 99.6%
False Positive Rate                              |█ <0.4%

Source: GRAIL PATHFINDER 2 study, presented at the 2026 American Society of Clinical Oncology Annual Meeting.

The 6.5-fold increase figure represents GRAIL’s headline result from the full PATHFINDER 2 cohort, describing how many more cancers were found when Galleri was layered on top of standard-of-care screening for breast, cervical, colorectal, and lung cancer, rather than relying on those recommended screenings alone. Because most standard screening programs only cover a handful of cancer types, adding a test capable of flagging signals across more than 50 cancer types naturally increases the total number of cancers caught in a screened population, even when the test misses many individual cases.

The 99.6% specificity and accompanying sub-0.4% false positive rate reinforce that Galleri’s core design tradeoff favors avoiding unnecessary alarm over maximizing detection sensitivity. This overview of colon cancer screening statistics provides useful context on how a single-cancer, well-established screening method compares against a newer multi-cancer approach still working through regulatory validation.

FDA Approval Status and Regulatory Timeline 2026

FDA Advisory Panel Votes (September 2026)
Safety                      |████████████████████████████████████████ 10-0 in favor
Benefits Outweigh Risks     |████████████████████████████████ 7-2, 1 abstention
Effectiveness               |████████████████████████ 6-4 in favor

Source: FDA premarket approval advisory panel proceedings, September 2026.

The FDA panel’s split vote on effectiveness, 6-4, stands out as the most contested result of the three votes taken, reflecting genuine disagreement among panel members about how to weigh Galleri’s modest overall sensitivity against its strong specificity and the population-level benefit demonstrated in PATHFINDER 2. The unanimous 10-0 safety vote suggests panel members found little concern about the test itself causing direct harm, with most of the debate centered instead on the downstream consequences of false positives and the workup burden they create.

An FDA advisory panel recommendation isn’t a final approval decision; the agency typically weighs panel input alongside its own review before issuing a final ruling on the premarket approval application submitted in January 2026. Until that formal approval happens, Galleri continues operating as a prescription-only, laboratory-developed test rather than an FDA-approved diagnostic, a distinction that carries real consequences for insurance coverage and clinical guideline inclusion.

The gap between advisory panel votes and a final FDA decision has historically run anywhere from a few weeks to several months for other premarket approval applications, so patients and clinicians watching this specific approval should expect the formal ruling sometime after this month’s panel meeting rather than an immediate announcement. Whatever the outcome, an approval would represent the first FDA clearance for any multi-cancer early detection test in the prescription screening category, a milestone none of Galleri’s competitors have yet reached either.

Cost and Insurance Coverage Statistics for Cancer Blood Tests 2026

List Price Comparison (Annual Test Cost)
Galleri (GRAIL)              |████████████████████████████████████████ $949
Cancerguard (Exact Sciences) |█████████████████████████████ $689

Source: GRAIL and Exact Sciences test pricing disclosures, and federal legislative records, 2026.

The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, which passed in February 2026, represents a genuine legislative milestone, but it establishes only a pathway for future Medicare coverage rather than granting immediate reimbursement. Actual coverage still depends on FDA approval status and a subsequent national coverage determination from the Centers for Medicare and Medicaid Services, meaning patients today largely pay the full list price out of pocket regardless of which MCED test they choose.

The roughly $260 price gap between Galleri and Cancerguard reflects differences in each company’s underlying technology and business strategy rather than a straightforward quality difference, since the two tests use different biomarker approaches and have been validated in different study populations. Without a US Preventive Services Task Force recommendation behind either product, most private insurers continue treating both tests as investigational, leaving affluent, self-pay patients as the primary current customer base for either test nationwide.

Employer-sponsored wellness programs have emerged as an unexpected secondary access point for these tests, with a small but growing number of large employers adding MCED screening as an optional benefit even without broader insurance mandates. That trend suggests some payers see enough preliminary value in early detection to justify covering the cost directly, even while the formal insurance and regulatory apparatus continues working through the slower process of establishing coverage criteria tied to FDA approval and USPSTF guidance.

Competing Multi-Cancer Blood Tests and Market Statistics 2026

MCED Market Overview
Projected CAGR, 2026-2035                       |████████████████████████████████ 17.7%
Cancers With No Recommended Screening           |████████████████████████████████ ~70%
Cancerguard Sensitivity, High-Mortality Cancers |█████████████████████████████ 68%

Source: Market research from Nova One Advisor and InsightAce Analytic, and Exact Sciences clinical data, 2026.

The nearly 70% figure describing cancers with no recommended standard screening explains why the entire MCED category exists in the first place: most cancer deaths in the US come from cancer types, like pancreatic, ovarian, and liver cancer, that have no equivalent to a mammogram or colonoscopy. Exact Sciences’ Cancerguard test, launched commercially in September 2025 at $689, reported a 68% sensitivity specifically for cancers with the lowest five-year survival rates, a figure the company positions as evidence its test targets exactly the cancers where early detection could matter most. This breakdown of cancer survival rate statistics by type shows just how wide the survival gap runs between cancers caught early versus late, underscoring why that screening gap carries such high stakes.

The market’s projected 17.7% compound annual growth rate through 2035 signals substantial investor and industry confidence in this technology category, even as individual tests continue working through regulatory approval and evidence generation. With GRAIL, Exact Sciences, Guardant Health, and Freenome all advancing competing platforms simultaneously, the coming years are likely to bring more head-to-head performance comparisons as each company publishes results from its own pivotal trials, adding to the broader picture tracked in this overview of cancer statistics in the US.

Frequently Asked Questions About Cancer Blood Test in US 2026

How accurate is the Galleri cancer blood test?

In the FDA’s review of PATHFINDER 2 data, Galleri showed 35.0% sensitivity and 99.85% specificity; GRAIL’s own analysis reported higher sensitivity, 69.8%, when limited to the 12 cancer types responsible for most cancer deaths, illustrating how much the reported figure depends on which subset of cancers is measured.

Is the Galleri test FDA approved?

No. As of this report’s publication, Galleri remains a prescription-only laboratory-developed test. An FDA advisory panel voted 7-2 in September 2026 that its benefits outweigh its risks, but the agency has not yet issued a final approval decision on the premarket approval application.

How much does the Galleri test cost?

Galleri lists at $949 and is rarely covered by private insurance or Medicare, since no US Preventive Services Task Force recommendation currently exists for the test.

How many types of cancer can Galleri detect?

Galleri is designed to detect signals from more than 50 types of cancer using a single blood draw.

What is the Galleri test’s positive predictive value?

Positive predictive value was 77% in the PATHFINDER 2 study and 66.2% in the NHS-Galleri trial, meaning most, but not all, positive results were later confirmed as actual cancer after diagnostic workup.

Does Medicare cover multi-cancer early detection tests?

Not yet automatically. The Nancy Gardner Sewell Medicare MCED Screening Coverage Act, passed in February 2026, creates a future coverage pathway, but actual reimbursement still depends on FDA approval and a separate Medicare coverage determination.

How well does Galleri detect early-stage cancer?

Galleri detected only 16.8% of Stage I cancers in its key validation study, compared with 90.1% of Stage IV cancers, showing the test performs far better on later-stage, more advanced disease.

What is Cancerguard, and how does it compare to Galleri?

Cancerguard, made by Exact Sciences, is a competing multi-cancer blood test priced at $689 that reported 68% sensitivity for the most deadly, low-survival cancers such as pancreatic and liver cancer.

How much does an MCED test increase cancer detection compared to standard screening?

In GRAIL’s PATHFINDER 2 study, adding Galleri to standard-of-care screening increased the number of cancers detected by up to 6.5-fold, with 71% of the newly found cancers caught at Stages I through III.

Why do so many cancers have no recommended screening test?

Nearly 70% of annual US cancer cases and deaths occur in cancer types, such as pancreatic and ovarian cancer, for which no standard screening test like a mammogram or colonoscopy currently exists, which is the core gap multi-cancer blood tests are designed to address.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE